The US Supreme Court's decision to uphold no-cost coverage for preventive care under the ACA is a major win for Gilead's new HIV PrEP shot, Yeztugo. Wells Fargo sees strong launch potential for it after the recent FDA approval. Analysts say the ruling supports broader access.